Progress in Radiopharmacy pp 110-124 | Cite as
Iodine Labelled 5-Iodo-2-Thiouracil as a Melanoma Seeking Agent: A Potential Drug for Diagnosis and Treatment
Chapter
Abstract
Adequate treatment of malignant melanoma places medical science before a difficult problem. Disseminated melanomas have poor prognoses. Moreover malignant melanomas are known to be radioresistant to a high degree. Recent investigations, however, cast doubt on this notorious reputation (1). It has been proposed that a high radiation dose per fraction, rather than total dose, may be a critical factor in the treatment of melanomas by means of irradiation (2,3).
Keywords
Melanoma Cell Clonogenic Assay Cytosine Arabinoside Melanin Content Syrian Golden Hamster
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Preview
Unable to display preview. Download preview PDF.
References
- 1.Trott KR, Von Lieven H, Kummermehr J, Skopal D, et al, The radiosensitivity of malignant melanomas. Part I. Experimental studies. Int. J. Radiat. Oncol. Biol. Phys. 7:9, 1981.PubMedCrossRefGoogle Scholar
- 2.Habermalz HF, Fisher JJ, Radiation therapy of malignant melanoma. Experience with high individual treatment dose. Cancer 38:2258, 1976.PubMedCrossRefGoogle Scholar
- 3.Hornsey S, The relationship between total dose, number of fractions and fraction size in the response of malignant melanoma in patients. Brit. J. Radiol. 51:905, 1978.PubMedCrossRefGoogle Scholar
- 4.Van Langevelde A, Bakker CNM, Broxterman HJ, Journée-de Korver JG, et al, Potential radiopharmaceuticals for the detection of ocular melanoma. Part I. 5-iodo-2-thiouracil derivates. Eur. J. Nucl. Med. 8:45, 1983.PubMedCrossRefGoogle Scholar
- 5.Larsson B, Olander K, Dencker L, Holmquist L, Accumulation of 125-I-labelled thiouracil and propylthiouracil in marine melanotic melanomas. Brit. J. Cancer 46:538, 1982.PubMedCrossRefGoogle Scholar
- 6.Fairchild RG, Packer S, Greenberg D, Som P, et al, Thiouracil distribution in mice carrying transplantable melanoma. Cancer Res. 42:5126, 1982.PubMedGoogle Scholar
- 7.Watts KP, Fairchild RG, Slatkin DN, Greenberg D, et al, Melanin content of hamster tissues, human tissues, and various melanomas. Cancer Res. 41:467, 1981.PubMedGoogle Scholar
- 8.Broxterman HJ, Van Langevelde A, Bakker CNM, Boer H, et al, Incorporation of (125-I)-5-iodo-2-thiouracil in cultured hamster, rabbit, and human melanoma cells. Cancer Res. 43:1316, 1983.PubMedGoogle Scholar
- 9.Packer S, Lambrecht RM, Cristman DR, Azzizullah N, et al, Metal isotopes used as radioactive indicators of ocular melanoma. Amer. J. Ophtal. 83:80, 1977.Google Scholar
- 10.Wick MM, Inhibition of clonogenic growth of melanoma cells by combination of melanocyte stimulating hormone and theophylline. J. invest. Derm. 77:253, 1981.PubMedCrossRefGoogle Scholar
- 11.Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, Protein measurements with the folin phenol reagent. J. biol. Chem. 193:265, 1951.PubMedGoogle Scholar
- 12.Camiener GW, Smith CG, Studies on the enzymatic deamination of cytosine arabinoside I. Enzymatic distribution and species specificity. Biochem. Pharmacol. 14:1405, 1965.PubMedCrossRefGoogle Scholar
- 13.Camiener GW, Studies on the enzymatic deamination of cytosine arabinoside II. Properties of the deaminase of human liver. Biochem. Pharmacol. 16:1681, 1967.PubMedCrossRefGoogle Scholar
- 14.Cheng YC, Capizzi RL, Enzymology of cytosine arabinoside. Med. Pediat. Oncol. 10(suppl.1):27, 1982.CrossRefGoogle Scholar
- 15.Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, 4-Norleucine,7-D-phenylanaline-α-melanocyte-stimulating hormone: A highly potent α-melanotropin with ultralong biological activity. Proc. nat. Acad. Sci, USA 77:5754, 1980.CrossRefGoogle Scholar
- 16.Dencker L, Larsson B, Olander K, Ullberg S, et al, False precursors of melanin as selective melanoma seekers. Brit. J. Cancer 39:449, 1979.PubMedCrossRefGoogle Scholar
Copyright information
© Martinus Nijhoff Publishers, Dordrecht 1986